Enquiry/Quote
Deflazacort 6 mg Tablet bulk supplier for pharma manufacturers

Deflazacort 6 Mg Tablet Suppliers & Bulk Manufacturers

Available Forms: Tablets

Available Strengths: 6 mg, 18 mg

Reference Brands: Emflaza (USA), Calcort (EU)

Category: Immune Disorder

Deflazocort is a synthetic corticosteroid used to treat inflammatory and autoimmune conditions, including muscular dystrophy, rheumatoid arthritis, and other chronic inflammatory disorders. It works by suppressing the immune system and reducing inflammation. Available in oral tablet and suspension forms, Deflazocort provides effective anti-inflammatory and immunosuppressive therapy with a relatively favorable side effect profile compared to other corticosteroids. Deflazacort 6 mg Tablet is available in Tablets and strengths such as 6 mg, 18 mg. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Deflazacort 6 mg Tablet is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.

Technical Specifications & Supply Details
Lead Time 7 to 60 days (depending on batch size & schedule)
MOQ As per manufacturer’s batch size
COA Available with every batch
Regulatory Dossier / DMF Available upon request
Export Documentation FSC, COA, Manufacturing License, Product Permission
Standards IP, BP, USP
Certifications WHO-GMP, EU-GMP, USFDA (as applicable)

Deflazacort 6 mg Tablet can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

📘 Sourcing Guide

Product Description:

Deflazacort, sold under the brand name Calcort among others, is a synthetic glucocorticoid belonging to the acetonide or O-isopropylidene derivative class. It is primarily used as an anti-inflammatory and immunosuppressive agent, helping to manage a variety of conditions involving inflammation or overactive immune responses. Deflazacort was first patented in 1969 and approved for medical use in 1985. It works by binding to glucocorticoid receptors, modulating gene expression, and reducing the production of inflammatory mediators in the body. The US Food and Drug Administration recognizes deflazacort as a first-in-class therapy for Duchenne Muscular Dystrophy, offering clinical benefits in slowing disease progression and improving muscle function. Its use extends to autoimmune disorders, allergic reactions, and other conditions requiring corticosteroid therapy, providing a balance of efficacy with a generally favorable safety profile compared to some other corticosteroids.

Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'

The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing

Frequently Asked Questions

Deflazacort is a corticosteroid medication used to reduce inflammation and suppress the immune system. It is commonly prescribed for conditions such as Duchenne muscular dystrophy, autoimmune disorders, allergic reactions, asthma, and certain inflammatory conditions.

Deflazacort is a synthetic glucocorticoid derivative of prednisolone. It works by binding to glucocorticoid receptors, modulating gene expression, and reducing the production of inflammatory mediators in the body.

Deflazacort is marketed under trade names such as Emflaza, Calcort, and Deflan.

Deflazacort is manufactured by companies including PTC Therapeutics (Emflaza) and various generic manufacturers worldwide.

The generic name is deflazacort.

Common brand names include Emflaza, Calcort, and Deflan.

Deflazacort is manufactured in multiple countries including the USA, EU nations, and India, following international pharmaceutical regulatory standards.

Yes, Deflazacort 6 mg Tablet is available with DMF and other regulatory documents such as COA and MSDS. These can be provided upon request for qualified buyers.

Absolutely. Sample requests are accepted for formulation trials and quality checks. Please submit an enquiry to initiate the process.

Our manufacturing partners are GMP-certified and comply with ISO and WHO standards, ensuring global quality benchmarks.

Lead times vary based on quantity and destination, but most orders are fulfilled within 1–3 weeks. Express shipping options are available.

Yes, Deflazacort 6 mg Tablet is exported to over 30 countries across Asia, Africa, Europe, and Latin America. We support documentation for customs and regulatory clearance.

Related Products

Avacopan

Strength:
10 mg

Form: Capsules

Reference Brands: Tavneos (USA/EU)

View Details
Fostamatinib Disodium

Strength:
100 mg, 150 mg

Form: Tablets

Reference Brands: Tavalisse (USA)

View Details
Deucravacitinib

Strength:
6 mg

Form: Tablet

Reference Brands: Sotyktu (USA/EU)

View Details
Auranofin

Strength:
3 mg

Form: Capsules

Reference Brands: Ridaura (USA)

View Details
Enquire Now

Quick Response Guaranteed | Verified Suppliers

Subscribe to Our Newsletter

Stay updated on pharma trends and marketplace opportunities.

Please enter the correct answer.
This website uses cookies to ensure you get the best experience. By using our site, you agree to our Privacy Policy.